Analyst Price Targets — MIST
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 10, 2026 9:33 am | — | Raymond James | $6.00 | $2.04 | TheFly | Milestone Pharmaceuticals initiated with a Strong Buy at Raymond James |
| December 16, 2025 11:45 am | Mohit Bansal | Wells Fargo | $8.00 | $2.34 | TheFly | Milestone Pharmaceuticals price target raised to $8 from $4 at Wells Fargo |
| December 15, 2025 2:47 pm | Brandon Folkes | H.C. Wainwright | $8.00 | $2.58 | TheFly | Milestone Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright |
| April 22, 2022 4:54 am | — | Piper Sandler | $10.00 | $7.15 | Benzinga | Piper Sandler Upgrades Milestone Pharmaceuticals to Overweight, Raises Price Target to $10 |
Latest News for MIST
MONTREAL and CHARLOTTE, N. C. , July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a total of 288,000 options (the "Options") to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the "Plan"), previously approved by the Company's Compensation Committee…
MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 288,000 options (the “Options”) to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the “Plan”), previously approved by the Company's Compensation Committee…
Alpha Cognition Inc. (Nasdaq: ACOG) (âAlpha Cognitionâ, or the âCompanyâ), a biopharmaceutical company focused on developing novel therapies for debili
Milestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks Transcript
Milestone Pharmaceuticals Inc. remains a Strong Buy, despite recent volatility and a 37% stock decline since FDA approval of Cardamyst. Cardamyst's rapid-acting efficacy, expanding insurance coverage, and unique market position underpin a compelling medium-term ramp in prescriptions and revenue. International expansion and a Phase 3 trial for AFib-RVR could significantly enlarge MIST's addressable market and…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MIST.
U.S. House Trading
No House trades found for MIST.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.